Amarin Corp Plc (AMRN)

[sts66]

Wow - this is sort of scary to think of, but understandable from a corporate perspective - AMRN may abandon the US market if they can't at least break even - the fate of V selling in the US is likely going to depend on this new BlinkRx patient access program increasing the number of patients who start and stay on V instead of quitting after 6 months.

https://seekingalpha.com/article/4479030-amarin-corporation-plc-amrn-ceo-karim-mikhail-presents-40th-annual-j-p-morgan-healthcare?messageid=2800&utm_campaign=4479030&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+Article+Smart

But for the moment, we have $0.5 billion business and its contribution margin positive. So we're not going to let go of this unless we really see that this is not sustainable, and we're not at this point

.

I don't want no stinking GV - AMRN had better pick up the pace in the US, because generics are eventually going to have more capacity - IIRC, more by the end of this year, plans are enough API to fill 50k weekly scripts, and AMRN goes margin negative well before that much GV is available unless they can get way more than 40% of payers to only cover V for the R-IT indication.

Also, anyone know what KM is talking about when he says "we reached 8,000 NBRx which we did not achieve for the last 15 months" - what is a new to brand Rx and how are they counted? Hikma didn't even start selling GV until Nov 2020, and that's less than 15 months ago, so all Rx before then were NBRx.